Oncotarget

Reviews:

Review: Oncolytic virotherapy, updates and future directions

Christos Fountzilas, Sukeshi Patel and Devalingam Mahalingam _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:102617-102639. https://doi.org/10.18632/oncotarget.18309

Metrics: PDF 3959 views  |   HTML 5398 views  |   ?  


Abstract

Christos Fountzilas1, Sukeshi Patel1 and Devalingam Mahalingam1

1The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Correspondence to:

Devalingam Mahalingam, email: Mahalingam@uthscsa.edu

Keywords: oncolytic virus, immunotherapy, cytotoxicity

Received: April 19, 2017     Accepted: May 03, 2017     Published: May 31, 2017

ABSTRACT

Oncolytic viruses (OVs) are viral strains that can infect and kill malignant cells while spare their normal counterparts. OVs can access cells through binding to receptors on their surface or through fusion with the plasma membrane and establish a lytic cycle in tumors, while leaving normal tissue essentially unharmed. Multiple viruses have been investigated in humans for the past century. IMLYGIC™ (T-VEC/Talimogene Laherparepvec), a genetically engineered Herpes Simplex Virus, is the first OV approved for use in the United States and the European Union for patients with locally advanced or non-resectable melanoma.

Although OVs have a favorable toxicity profile and are impressively active anticancer agents in vitro and in vivo the majority of OVs have limited clinical efficacy as a single agent. While a virus-induced antitumor immune response can enhance oncolysis, when OVs are used systemically, the antiviral immune response can prevent the virus reaching the tumor tissue and having a therapeutic effect. Intratumoral administration can provide direct access to tumor tissue and be beneficial in reducing side effects.

Immune checkpoint stimulation in tumor tissue has been noted after OV therapy and can be a natural response to viral-induced oncolysis. Also for immune checkpoint inhibition to be effective in treating cancer, an immune response to tumor neoantigens and an inflamed tumor microenvironment are required, both of which treatment with an OV may provide. Therefore, direct and indirect mechanisms of tumor killing provide rationale for clinical trials investigating the combination of OVs other forms of cancer therapy, including immune checkpoint inhibition.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18309